Publication:
Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).

dc.contributor.authorRosen, Raymond C
dc.contributor.authorWu, Frederick
dc.contributor.authorBehre, Hermann M
dc.contributor.authorPorst, Hartmut
dc.contributor.authorMeuleman, Eric J H
dc.contributor.authorMaggi, Mario
dc.contributor.authorRomero-Otero, Javier
dc.contributor.authorMartinez-Salamanca, Juan I
dc.contributor.authorJones, Thomas Hugh
dc.contributor.authorDebruyne, Frans M J
dc.contributor.authorKurth, Karl-Heinz
dc.contributor.authorHackett, Geoff I
dc.contributor.authorQuinton, Richard
dc.contributor.authorStroberg, Peter
dc.contributor.authorReisman, Yacov
dc.contributor.authorPescatori, Edoardo S
dc.contributor.authorMorales, Antonio
dc.contributor.authorBassas, Lluis
dc.contributor.authorCruz, Natalio
dc.contributor.authorCunningham, Glenn R
dc.contributor.authorWheaton, Olivia A
dc.contributor.authorRHYME Investigators
dc.date.accessioned2023-01-25T09:50:13Z
dc.date.available2023-01-25T09:50:13Z
dc.date.issued2017-08-07
dc.description.abstractThe benefits and risks of long-term testosterone administration have been a topic of much scientific and regulatory interest in recent years. To assess long-term quality of life (QOL) and sexual function benefits of testosterone replacement therapy (TRT) prospectively in a diverse, multinational cohort of men with hypogonadism. A multinational patient registry was used to assess long-term changes associated with TRT in middle-age and older men with hypogonadism. Comprehensive evaluations were conducted at 6, 12, 24, and 36 months after enrollment into the registry. QOL and sexual function were evaluated by validated measures, including the Aging Males' Symptom (AMS) Scale and the International Index of Erectile Function (IIEF). A total of 999 previously untreated men with hypogonadism were enrolled at 25 European centers, 750 of whom received TRT at at least one visit during the period of observation. Patients on TRT reported rapid and sustained improvements in QOL, with fewer sexual, psychological, and somatic symptoms. Modest improvements in QOL and sexual function, including erectile function, also were noted in RHYME patients not on TRT, although treated patients showed consistently greater benefit over time in all symptom domains compared with untreated patients. AMS total scores for patients on TRT were 32.8 (95% confidence interval = 31.3-34.4) compared with 36.6 (95% confidence interval = 34.8-38.5) for untreated patients (P  TRT-related benefits in QOL and sexual function are well maintained for up to 36 months after initiation of treatment. The major strengths are the large, diverse patient population being treated in multidisciplinary clinical settings. The major limitation is the frequency of switching from one formulation to another. Overall, we confirmed the broad and sustained benefits of TRT across major QOL dimensions, including sexual, somatic, and psychological health, which were sustained over 36 months in our treatment cohort. Rosen RC, Wu F, Behre H, et al. Quality of Life and Sexual Function Benefits Effects of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME). J Sex Med 2017;14:1104-1115.
dc.identifier.doi10.1016/j.jsxm.2017.07.004
dc.identifier.essn1743-6109
dc.identifier.pmid28781213
dc.identifier.unpaywallURLhttps://discovery.ucl.ac.uk/10053588/1/Quality%20of%20Life%20and%20Sexual%20Function%20Benefits%20Effects%20of%20Long-Term%20Testosterone.pdf
dc.identifier.urihttp://hdl.handle.net/10668/11479
dc.issue.number9
dc.journal.titleThe journal of sexual medicine
dc.journal.titleabbreviationJ Sex Med
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number1104-1115
dc.pubmedtypeJournal Article
dc.pubmedtypeRandomized Controlled Trial
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectHypogonadism
dc.subjectPhosphodiesterase Type 5 Inhibitors
dc.subjectQuality of Life
dc.subjectSexual Function
dc.subjectTestosterone Replacement Therapy
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshCohort Studies
dc.subject.meshEurope
dc.subject.meshHormone Replacement Therapy
dc.subject.meshHumans
dc.subject.meshHypogonadism
dc.subject.meshLongitudinal Studies
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPenile Erection
dc.subject.meshProspective Studies
dc.subject.meshQuality of Life
dc.subject.meshRegistries
dc.subject.meshSexual Behavior
dc.subject.meshTestosterone
dc.subject.meshYoung Adult
dc.titleQuality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
dc.typeresearch article
dc.type.hasVersionAM
dc.volume.number14
dspace.entity.typePublication

Files